July 2016 ARTICLE LIST >>
PharmaTutor (July- 2016)
Print-ISSN: 2394 - 6679
e-ISSN: 2347 - 7881
(Volume 4, Issue 7)
Received On: 08/02/2016; Accepted On: 29/02/2016; Published On: 01/07/2016
AUTHORS:
Hemendrasinh J Rathod*, Dhruti P. Mehta, Jitendra Singh Yadav
Department of Pharmaceutics, Vidyabharti Trust College of Pharmacy,
Umrakh, Gujarat, India.
*hariomh.j.rathod@gmail.com
ABSTRACT: The purpose of writing the review on gastroretentive drug delivery systems (GRDDS) was to accumulate the current literature with a special emphasis on several gastroretentive approaches that have recently become important methodologies in the field of site-specific orally administered sustained/controlled release drug delivery. Technological efforts have been made in research and development of rate-controlled oral drug delivery systems to solve physiological difficulties, like short gastric residence times (GRT) and unpredictable gastric emptying times (GET). GRDDS are an approach to prolong the GRT, thereby targeting site-specific drug release in the upper gastrointestinal tract (GIT) for local or systemic effect. Conventional oral dosage forms pose low bioavailability problems because of their quick gastric transition from the stomach, particularly in case of drugs that are less soluble at an alkaline pH of the intestine. Also, drugs that produce their local action in the stomach get quickly emptied and don’t get sufficient residence time in the stomach. Several efforts have been made to extend the retention time of drug delivery system to reduce the frequency of dose administration. GRDFs not only prolong dosing intervals, but also increase patient compliance beyond the level of existing controlled release dosage forms. This article gives an overview on advantages, disadvantages and characterization of gastroretentive drug delivery systems. This review also includes commercially available gastroretentive products and patents.
How to cite this article: Rathod HJ, Mehta DP, Yadav JS; A review on Gastroretentive Drug Delivery Systems; PharmaTutor; 2016; 4(7); 29-40
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. Kagan L, Hoffman A; Systems for region selective drug delivery in gastrointestinal tract; biopharmaceutical considerations; Expert Opinion on Drug Delivery; 2008; 5(6); 681-692.
2. Bardonnet P, Faivre V, Pugh W, Piffaretti J, Falson F; Gastroretentive dosage forms, Overview and special case of Helicobacter pylori; Journal of Controlled Release; 2006; 111; 1-18.
3. Deshpande AA, Shah NH, Rhodes CT, Malick W; Development of a novel controlled release system for gastric retention; Pharmaceutical Research; 1997; 14(6); 815‐819.
4. Patil, JM, Hirlekar RS, Gide PS, Kadam VJ; Trends in floating drug delivery system; Journal of Scientific and Industrial Research; 2006; 65; 11-21.
5. Arunachalam A, Karthikeyan M, Konam K, Prasad HP, Sethuraman S, Ashutoshkumar S, Manidipa S; Floating drug delivery systems: A Review; International Journal of Pharmaceutical Science and Research; 2011; 2(1); 76-83.
6. Tortora GJ, Grabowski SR. Principles of Anatomy and Physiology; New York; John Wiley and Sons; 2002.
7. Marinaganti RK, Bonthu S, Nagakanyaka DP, Sheik M; A comprehensive review on gastro retentive drug delivery system; 2013; 3(2); 149-164.
8. Garg S, Sharma S; Gastroretentive Drug Delivery System; Business Briefing: Pharmatech; 2003; 160‐166.
9. Brahmankar DM, Jaiswal SB; Biopharmaceutics and pharmacokinetics a treatise; New Delhi; Vallabh Prakashan; 2003.
10. Patel GM, Patel HR, Patel M; Floating drug delivery system: An innovative approach to prolong gastric retention; Pharmainfo.net 2007; 5(6).
11. Jain NK; Progress in controlled and novel drug delivery system; Delhi; CBS Publishers; 2003.
12. Babu VBM, Khar RK; In vitro and In vivo studies of sustained release floating dosage forms containing salbutamol sulphate; Pharmazie; 1990; 45(4); 268-270.
13. Nasa P, Mahant S, Sharma D; Floating systems: a novel approach towards gastroretentive drug delivery systems; International Journal of Pharmacy and Pharmaceutical Sciences; 2010; 2(3); 2-7.
14. Reddy LH, Murthy RS; Floating dosage systems in drug delivery; Critical reviews in therapeutic drug carrier systems; 2002; 19(6); 553-585.
15. Shah SH, Patel JK, Pundarikakshudu K, Patel NV; An overview of a gastroretentive floating drug delivery system; Asian Journal of Pharmaceutical Sciences; 2009; 4(1); 65-80.
16. Gupta G, Singh A; A Short Review on Stomach Specific Drug Delivery System; International Journal of PharmTech Research; 2012; 4(4); 1527-1545.
17. Rubinstein A, Friend DR; Specific delivery to the gastrointestinal tract; In: Domb AJ, editor; Polymeric Site-Specific Pharmacotherapy; Wiley & Chichester; 1994; 282-283.
18. Ikura, H, Suzuki Y, Nagai T, Machida Y, inventors; Teijin Limited, assignee; Cellulose ether, polyacrylic acid, foaming agent, drug; United States Patent US 4777033 A; 1988 Oct 11.
19. Umezawa H, inventor; Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai, assignee; Pepstatin floating minicapsules; United States Patent US 4101650 A; 1978 Jul 18.
20. Fabrcgas JL, Cucala CG, Pous J; Sites R.A. In vitro testing of an antacid formulation with prolonged gastric residence time; Drug Development and Industrial Pharmacy; 1994; 20; 1199-1212.
21. Agnihotri SA, Jawalkar SS, Aminabhavi TM; Controlled release of cephalexin through gellan gum beads: Effect of formulation parameters on entrapment efficiency, size, and drug release, European Journal of Pharmaceutics and Biopharmaceutics; 2006; 63(3); 249-261.
22. Harries D, Sharma HL; GI transit of potential bioadhesive formulations in man: A scintigraphic study; Journal of Controlled Release; 1990; 12(1); 45-53.
.png)
